CytomX Therapeutics (CTMX) 10-Q2024 Q1 Quarterly report

Filed: 8 May 24, 4:01pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: Adequacy, arthralgia, auristatin, Barbara, Bayesian, bill, BIOSECURE, BOIN, burdensome, central, characteristic, contemplate, content, cornerstone, CRC, CRS, cutoff, device, disgorgement, DPF, dysregulated, earned, essential, feedback, formatting, gastric, GLP, highest, home, House, indirect, infiltration, Interval, introduced, iron, Janux, KEYTRUDA, longevity, margination, mechanism, median, mg, monomethyl, NSCLC, occurrence, outweigh, pancreatic, pharmacodynamic, pharmacokinetic, proof, protest, proxy, rash, RECIST, rejection, renal, rendering, Santa, Senate, sought, syndrome, TCE, tocilizumab, toxicology, transferrin, transform, tubulin, unannounced, underway, University, unreliable, uptake, verity, vision, vomiting, wholly

Removed: AE, AEs, arm, attestation, borrowing, breast, broaden, centerpiece, cGMP, classified, closely, Colorado, Connecticut, defining, deprioritized, diffuse, discontinuation, distancing, DLBCL, dosage, emerge, enabling, encouraging, Enhancing, EU, evaluable, exacerbate, examined, exemption, gastrointestinal, geographic, globe, Harpoon, hepatocellular, histology, hormone, implicit, improving, inaccessible, incremental, injunction, innovative, Intelligence, internally, invalidated, liver, lymphoma, metabolic, monotherapy, nivolumab, ocular, ORR, poorly, praluzatamb, prioritized, promotional, prostate, randomized, rarity, regime, rental, Revitope, ROU, Shield, shown, snapshot, stopped, TCB, TNBC, today, TRAE, transcend, unselected, Utah, Virginia, worse

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Associated CTMX transcripts

CTMX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CytomX Therapeutics, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Christopher W. Ogden, Senior Vice President, Finance and Accounting of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (the “Act”), that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 8, 2024	By:	/s/ Christopher W. Ogden
	Name:	Christopher W. Ogden
	Title:	Senior Vice President, Finance and Accounting
		(Principal Accounting Officer)

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of CytomX Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.